Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Azurity Pharmaceuticals, Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume suggests a focused prosecution phase for the company's current patent interests, where each filing receives significant individual attention.
The portfolio is distributed across a corresponding number of distinct examiners and 2 distinct art units. This distribution indicates that each pending matter is being handled in a separate specialized section of the patent office, requiring a strategy that addresses the specific technical standards of different administrative units.
SOROUSH, LAYLA is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because this examiner is responsible for a specific portion of the total filings, their individual examination style will influence the company's immediate legal outcomes. Practitioners should monitor these individual examiner trends to anticipate potential hurdles, as the 1 pending office action under this examiner represents a key focal point for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 10d overdue |
| 18925887 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18925887 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | SOROUSH, LAYLA | 1622 | DP | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Final Rejection | 10d overdue | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAzurity Pharmaceuticals, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Layla Soroush has the most, with 1 of Azurity Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
